Pancreatic cancer is the fifth most common cause of cancer in the U.S. The majority of patients present with incurable disease, and of those that are candidates for surgical resection by pancreaticoduo-denectomy, few survive five years. In colorectal cancer also, earlier diagnosis would be of great value. The board objective of this proposal is to explore the possibility of practical screening and diagnostic tests for pancreatic and colorectal cancer based on detection of mutant genes in routine clinical samples such as stool, so as to allow earlier diagnosis. Specifically, this study will detect ras gene mutations in such samples, compare results in pancreatic cancer and in colorectal neoplasms, determine whether atypical duct lesions are the precursor of pancreatic cancer and whether they are the source of the cells which enter the gastrointestinal tract, and develop second stage stool assays based on other mutant genes to serve as tests for confirmation of the ras assay results. These studies will include patients with colorectal adenomas and carcinomas, resectable and unresectable pancreatic exocrine adenocarcinoma, benign pancreatic duct disease, chronic pancreatitis, and colorectal adenomas and carcinomas. Three forms of assay are available, and positive results in one will be confirmed using a different system. This study will focus on routine samples such as stool and blood, and will not emphasize invasive and expensive diagnostic samples such as pancreatic secretions and cytologic samples. The methods used to sensitively detect rare mutant DNA sequences in routine specimens will be readily transferable to the more specialized clinical material.
The aim i s to develop clinical tests for general use that will allow a real impact on early diagnosis. Aspects of this study benefit directly from the findings of the companion project 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA062924-03S1
Application #
5209333
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205
Chu, Nam; Salguero, Antonieta L; Liu, Albert Z et al. (2018) Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis. Cell 174:897-907.e14
Felsenstein, Matthäus; Noë, Michaël; Masica, David L et al. (2018) IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut 67:1652-1662
Grant, Robert C; Denroche, Robert E; Borgida, Ayelet et al. (2018) Exome-Wide Association Study of Pancreatic Cancer Risk. Gastroenterology 154:719-722.e3
Tie, Jeanne; Cohen, Joshua D; Wang, Yuxuan et al. (2018) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut :
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Ma, Qianqian; Gabelli, Sandra B; Raben, Daniel M (2018) Diacylglycerol kinases: Relationship to other lipid kinases. Adv Biol Regul :

Showing the most recent 10 out of 883 publications